RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification
American Journal of Translational Research · 2026 · 18 (10) · 9251-9269
DOI: 10.62347/jnce1282 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Translational Research, 2026. Verfasst von Xuemei Sun und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sun, X., Luo, Q., Yan, S., Yang, F., Zhou, J., Yang, F., Cheng, Y., Yang, W., & Li, Y. (2026). RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification. American Journal of Translational Research, 18(10), 9251-9269. https://doi.org/10.62347/jnce1282
Vancouver
Sun X, Luo Q, Yan S, Yang F, Zhou J, Yang F, et al. RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification. American Journal of Translational Research. 2026;18(10):9251-9269. doi:10.62347/jnce1282
BibTeX
@article{Sun2026,
author = {Sun, Xuemei and Luo, Qingqing and Yan, Shen and Yang, Fuli and Zhou, Jiajun and Yang, Fanze and Cheng, Yijing and Yang, Wandong and Li, Yongfeng},
title = {RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification},
journal = {American Journal of Translational Research},
year = {2026},
volume = {18},
number = {10},
pages = {9251--9269},
doi = {10.62347/jnce1282}
}
EUVIMED